ReviewTrends in immunology2021
Archetypes of checkpoint-responsive immunity.
Review in Trends in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Differential assembly of mouse and human tumor microenvironments.Nature immunology · 2026Article
- Spatial analysis of tumor immune microenvironment of TNBC with different neoadjuvant chemotherapy outcomes using multiplex Immunofluorescence.Breast cancer research : BCR · 2025Article
- Stage-dependent spatial distribution and prognostic value of CD8NPJ precision oncology · 2025Article
- Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis.The Journal of experimental medicine · 2025Article
- IL-18-primed NK cells recruit dendritic cells and potentiate tumor therapy mediated by PD-1 blockade.Frontiers in oncology · 2025Article
- Critical role of CD206+ macrophages in promoting a cDC1-NK-CD8 T cell anti-tumor immune axis.bioRxiv : the preprint server for biology · 2024Article
- The war between the immune system and the tumor - using immune biomarkers as tracers.Biomarker research · 2024Review
- Bridging the Gap between Innate and Adaptive Immunity in the Lung: Summary of the Aspen Lung Conference 2022.American journal of respiratory cell and molecular biology · 2023Article
- Defining and using immune archetypes to classify and treat cancer.Nature reviews. Cancer · 2023Review
- Identification of stromal cell proportion-related genes in the breast cancer tumor microenvironment using CorDelSFS feature selection: implications for tumor progression and prognosis.Frontiers in genetics · 2023Article
- Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Responsiveness to immune checkpoint blockade (ICB) therapy in cancer is currently predicted by disparate individual measures - with varying degrees of accuracy - including tumor mutation burden, tumor-infiltrating T cell densities, dendritic cell frequencies, and the expression of checkpoint ligands. We propose that many of these individual parameters are linked, forming two distinct 'reactive' immune archetypes - collections of cells and gene expression - in ICB-responsive patients. We hypothesize that these are 'seeds' of antitumor immunity and are supported by specific elements of the tumor microenvironment (TME) and by actions of the microbiome. Although removing 'immunosuppressive' factors in the TME is important, understanding and parsing reactive immunity is crucial for optimal prognosis and for engaging this biology with candidate therapies to increase tumor cure rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.